Document Detail


Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.
MedLine Citation:
PMID:  20184211     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clobetasol propionate (CP) shampoo 0.05% is an efficacious and safe treatment for scalp psoriasis. The aim of this double-blind, randomized, placebo-controlled study was to determine if CP shampoo is suitable for long-term disease control. Participants with moderate to severe scalp psoriasis (global severity score [GSS] of 3 or 4 on a scale of 0 [clear] to 5 [very severe]) first received once daily CP shampoo treatment for up to 4 weeks. Responders were subsequently randomized to receive the CP shampoo or vehicle twice weekly maintenance regimen for up to 6 months. When relapse occurred (defined as GSS > 2), participants resumed once daily CP shampoo treatment; when symptoms diminished (GSS < or = 2), they readopted the twice weekly maintenance regimen. At all visits significantly more participants treated with CP shampoo did not relapse compared with participants treated with vehicle (P < .001). Only approximately one-third of participants treated with vehicle remained relapse free at 1 month, while this rate was observed approximately 3.5 months later (4.5 months after baseline of maintenance phase) in the CP shampoo group. After 6 months 31.1% (33/106) of participants in the CP shampoo group were still relapse free versus 8.1% (9/111) of participants in the vehicle group. There was no greater incidence of skin atrophy, telangiectasia, or hypothalamic-pituitary-adrenal (HPA) axis suppression in the CP shampoo group compared with the vehicle group. Clobetasol propionate shampoo is efficacious and safe for acute management and long-term maintenance of moderate to severe scalp psoriasis.
Authors:
Yves Poulin; Kim Papp; Robert Bissonnette; Lyn Guenther; Jerry Tan; Charles Lynde; Nabil Kerrouche; Hervé Villemagne;
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cutis     Volume:  85     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-26     Completed Date:  2010-03-25     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  43-50     Citation Subset:  IM    
Affiliation:
Centre de Recherche Dermatologique du Québec Metropolitain, Québec City, Québec, Canada. poulinyves@videotron.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Clobetasol / administration & dosage,  adverse effects,  therapeutic use*
Double-Blind Method
Female
Glucocorticoids / administration & dosage,  adverse effects,  therapeutic use*
Hair Preparations
Humans
Male
Middle Aged
Psoriasis / drug therapy*,  pathology
Recurrence
Scalp Dermatoses / drug therapy*,  pathology
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Glucocorticoids; 0/Hair Preparations; 25122-41-2/Clobetasol
Investigator
Investigator/Affiliation:
Kirk Barber / ; David Gratton / ; Harvey Lui / ; Richard Thomas / ; Ronald Vender / ; Beatrice Wang / ; Y May Ma / ; Zeina Saab /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inoculation bartonellosis in an adult: a case report.
Next Document:  Cognitive effects of GABAergic antiepileptic drugs.